NASDAQ-listed Enveric Acquires MagicMed to Bring Psychedelics Derivatives to Market

纳斯达克上市的Enveric收购MagicMed将迷幻药衍生品推向市场

2021-05-25 20:00:12 CFN Media Group

本文共1383个字,阅读需4分钟

 Enveric Biosciences (NASDAQ: ENVB), best-known for its pipeline of naturally occurring cannabinoid compounds, recently entered into a definitive agreement to acquire MagicMed Industries, a private biotechnology company focused on building a library of novel derivative psychedelic molecules with applications across multiple indications. The transaction broadens Enveric Bioscience’s focus into psychedelics and complements its existing pipeline of naturally occurring cannabinoid compounds. In addition to its current focus on oncology, the move will enable the company to move into the clinic with novel therapies across oncology and central nervous system disorders, such as PTSD. Upon closing of the transaction, MagicMed’s Dr. Joseph Tucker will be appointed Chief Executive Officer of Enveric Biosciences. Dr. Tucker is a seasoned executive that has built several publicly traded companies, including Stem Cell Therapeutics and Epimeron Inc., which became a part of Willow Biosciences Inc. during its original formation. Enveric Biosciences has traditionally focused on identifying and developing undervalued, under-researched and naturally occurring cannabinoid compounds in partnership with leading clinics. With existing anecdotal evidence and strong patient and clinician interest, these compounds were focused on oncological conditions, such as GBM, and palliative care. MagicMed has focused on creating a library of molecular derivatives of psilocybin and DMT, among other psychedelics. By combining non-patentable naturally occurring molecules with other building blocks, the company aims to create derivative molecules that are both patentable and customized to target specific diseases or conditions. With the acquisition of MagicMed, Enveric Biosciences gains access to this robust derivatives library—the Psybrary™—consisting of a collection of novel psychedelic-derivative drug candidates, manufacturing methods, pharmacological data and patent filings. MagicMed has already filed 14 patent applications covering over 125 million individual molecules. The acquisition combines this sprawling psychedelic derivative library with Enveric Bioscience’s experienced clinical team to bring its pipeline of molecules through the clinic to help serve millions of patients suffering from mental health conditions around the world. The combined platform targets a massive total addressable market underserved by today’s drugs. MagicMed’s acquisition by Enveric Biosciences represents a major leap forward for both businesses. As a NASDAQ-listed company, Enveric Biosciences has significant liquidity and capital market resources, setting it apart from many other psychedelic-focused companies that trade on junior stock exchanges, like the OTC Markets. “Our proposed acquisition of MagicMed underscores the core fundamental mission of Enveric to form a drug discovery and clinical-stage biotechnology company with a focus on bringing forward nature-originated therapies to improve the standard of care and serve unmet needs in oncology and CNS indications,” said David Johnson, CEO of Enveric Biosciences. With more than 200+ distinct psilocybin-derivative drug candidates synthesized at MagicMed’s state-of-the-art R&D facility in Calgary, the combined company has a psychedelics portfolio that’s ripe for near-term clinical development along with an experienced clinical development team that’s well-equipped to drive long-term shareholder value. For more information, visit the company’s website or download their investor presentation. This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Enveric Biosciences(纳斯达克代码:ENVB)以其天然大麻素化合物的管道而闻名,最近与一家私营生物技术公司MagicMed Industries达成了一项最终协议,该公司专注于建立一个具有多种用途的新型衍生物迷幻分子库。 这笔交易将Enveric Bioscience的重点扩大到迷幻药,并补充了其现有的天然大麻素化合物的生产渠道。除了目前专注于肿瘤学之外,这一举措将使该公司能够以跨越肿瘤学和中枢神经系统疾病(如PTSD)的新疗法进入诊所。 交易完成后,MagicMed的Joseph Tucker博士将被任命为Enveric Biosciences的首席执行官。塔克博士是一位经验丰富的高管,创建了几家上市公司,包括干细胞治疗公司和Epimeron Inc.,后者在Willow Biosciences Inc.最初成立时成为其一部分。 Enveric Biosciences传统上侧重于与主要诊所合作,鉴定和开发价值低、研究不足和天然存在的大麻素化合物。由于现有的轶事证据以及患者和临床医生的强烈兴趣,这些化合物被集中于肿瘤学条件,如GBM,和姑息治疗。 MagicMed专注于建立一个psilocybin和DMT等迷幻剂的分子衍生物库。通过将不可专利的天然存在的分子与其他构件相结合,该公司旨在创造既可专利又可针对特定疾病或条件定制的衍生分子。 随着MagicMed的收购,Enveric Biosciences获得了这个强大的衍生物库--精神病™--包括一系列新的迷幻衍生物候选药物、制造方法、药理数据和专利文件。MagicMed已经提交了14项专利申请,覆盖了超过1.25亿个单个分子。 此次收购将这个庞大的迷幻衍生物库与Enveric Bioscience经验丰富的临床团队结合起来,将其分子管道通过诊所,帮助为世界各地数百万患有精神健康状况的患者提供服务。合并后的平台瞄准了一个目前药物服务不足的巨大的可寻址市场。 MagicMed被Enveric Biosciences收购代表了两家公司的一个重大飞跃。作为一家在纳斯达克上市的公司,Enveric Biosciences拥有巨大的流动性和资本市场资源,这使它与许多其他专注于迷幻的公司区别开来,这些公司在初级证券交易所(如OTC市场)进行交易。 Enveric Biosciences公司首席执行官大卫·约翰逊说:“我们对MagicMed的拟议收购强调了Enveric公司的核心基本使命,即成立一家药物研发和临床阶段生物技术公司,专注于提出自然疗法,以提高护理标准,并满足肿瘤和中枢神经系统适应症方面未得到满足的需求。” 在MagicMed位于卡尔加里的最先进的研发设施中合成了200多种不同的Psilocybin衍生物候选药物,合并后的公司拥有一个适合近期临床开发的迷幻药组合,同时拥有一支经验丰富的临床开发团队,能够为股东带来长期价值。 欲了解更多信息,请访问该公司网站或下载其投资者演示文稿。 本文由CFN Enterprises Inc.(OTCQB:CNFN)发表,该公司是CFN Media的所有者和运营商,CFN Media是该行业的领先机构,也是致力于新兴的CBD和合法大麻行业的数字金融媒体网络。欲了解更多信息,请致电+1(833)420-CNFN。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文